PIK3CD and acute myeloid leukemia: Moving forward, a larger-scale clinical trial involving TN and R/R AML patients, representing different cytogenetic and mutational subtypes (e.g., FLT3-ITD+ patients with constitutive PI3K pathway activation), is necessary to fully ascertain the therapeutic potential of duvelisib and other PI3K isoform-selective inhibitors of AML.